More Bad News for Valeant Pharmaceuticals Intl Inc.

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) will be subject to even more public scrutiny.

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) interim CEO Howard Schiller will be testifying in front of a U.S. congressional panel next week. The focus of his testimony will be the severe price hikes on two drugs, Isuprel and Nitropress.

So what exactly does this mean for Valeant and its shareholders?

The drugs in question

Valeant acquired Isuprel and Nitropress, both of which are used to treat heart attacks, in February of last year. Then it immediately hiked the price of the drugs by 212% and 525% respectively, according to The Wall Street Journal. At the time, a Valeant spokeswoman stated bluntly that the company’s goal was to “maximize the value” of every drug to the company’s shareholders.

Politics are working against Valeant

Congress was not amused and requested information from Valeant about the revenue, costs, and expenses for these drugs.

Things got a whole lot worse in September when biotech entrepreneur Martin Shkreli acquired the rights to Daraprim (a drug used to treat toxoplasmosis, a life-threatening parasitic infection) and then raised the drug’s price by 5,000%. Mr. Shkreli’s actions angered a lot of people and even drew a quick response from Hillary Clinton. All of a sudden, the spotlight was squarely on drug-price increases, and Valeant was caught up in the mix.

To put it bluntly, Mr. Shkreli has effectively poisoned the well for Valeant. Even PhRMA, which lobbies on behalf of pharmaceutical companies, has felt compelled to distance itself from the two. So it cannot be good news that Mr. Shkreli will also be testifying at the same hearing.

Granted, you can never count on Washington politicians to accomplish anything. So there’s a chance that all of this fury won’t lead to any new legislation. But polls have shown that this is a bipartisan issue–some even suggest that Republicans want regulations on drug prices as much as they want Obamacare repealed. Furthermore, one study showed that drug prices come under pressure when the issue is being debated by politicians.

Drug regulation could have a profound impact on Valeant. According to an analysis performed last year, Valeant would lose over US$300 million per year if Isuprel and Nitropress prices reverted back to 2014 levels. And neither were even among Valeant’s top six drugs.

Bigger issues down the line

Unfortunately for Valeant, new legislation is the least of its worries.

Remember, the company has faced criticism for its serial acquisitions, steep drug-price hikes, and its relationship with captive pharmacies. Even if there’s no new legislation, none of those tactics will be employed this year. And we’ll get to see Valeant for what it’s really worth.

So if you think this stock looks cheap, you should tread very carefully and at least wait until next week is over.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

stock research, analyze data
Dividend Stocks

How Much to Invest to Get $500 in Dividends Every Month

TSX dividend stocks such as Enbridge, TD Bank, and Telus, can help you earn $500 in monthly dividend payments.

Read more »

A solar cell panel generates power in a country mountain landscape.
Energy Stocks

Clean Energy Play: Is Brookfield Renewable a Good Stock for a TFSA?

Add this top renewable energy stock to your self-directed TFSA portfolio for significant long-term and tax-free wealth growth.

Read more »

Golden crown on a red velvet background
Dividend Stocks

Dividend Powerhouses: Canadian Stocks to Fuel Your Portfolio

These two top Canadian dividend aristocrats are some of the top stocks on the TSX to buy now and hold…

Read more »

Dial moving from 4G to 5G
Dividend Stocks

This Undervalued Dividend Stock is Worth Buying Right Now

Want an undervalued dividend stock with long-term potential and a juicy yield? Here's an option you may regret not buying…

Read more »

A worker gives a business presentation.
Dividend Stocks

1 Stock I’m Buying Hand Over Fist in July Despite the Market’s Pessimism

This top dividend stock is going through a rough patch, but don't let that count out all the growth we've…

Read more »

financial freedom sign
Investing

2 Stocks With Millionaire-Maker Potential

These two top Canadian stocks are among the best on the TSX, and each has the potential to be millionaire-maker…

Read more »

Piggy bank next to a financial report
Stocks for Beginners

Is It Finally the Right Time to Buy Bank Stocks?

Canadian bank stocks are some of the most secure investments out there, but of them all, this bank stock is…

Read more »

clock time
Investing

3 Blue-Chip Stocks Every Canadian Should Own

Want some reliable blue-chip Canadian stocks to buy and hold for the next 10 years? These three stocks are worth…

Read more »